<DOC>
	<DOCNO>NCT00432406</DOCNO>
	<brief_summary>The purpose study : - To elucidate immunomodulating property anti-TNF-α therapy patient psoriatic arthritis ( PsA ) . - To ascertain whether magnetic resonance imaging ( MRI ) sensitive tool measure early response therapy anti-TNF-α PsA wrist use Outcome Measures Rheumatoid Arthritis Clinical Trials ( OMERACT ) guideline rheumatoid arthritis ( RA ) . - To assess whether lipid cardiovascular risk profile would improve anti-TNF-α therapy patient PsA .</brief_summary>
	<brief_title>Tumor Necrosis Factors ( TNF ) -α Blockade Psoriatic Arthritis</brief_title>
	<detailed_description>The study 12-week , open-label trial anti-TNF therapy 20 consecutive patient ( Group 1 ) . Another 20 consecutive patient active disease meet exclusion criterion , unwilling start anti-TNF therapy fear toxicity would recruit control patient ( Group 2 ) . 20 healthy control recruit comparison metabolic risk factor ( Group 3 ) . Study visit group 1 2 conducted baseline , week 2 6 , week 12 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Age 18 PsA active disease despite treatment nonsteroidal antiinflammatory drug ( NSAID ) 3 swollen tender joint Inadequate response 4 week , intolerance nonsteroidal antiinflammatory drug therapy . Methotrexate ( MTX ) allow study take least 3 month previously , dosage stable least 4 week prior baseline visit . Prednisone ≤ 10 mg/day and/or nonsteroidal antiinflammatory drug must take stable dosage least 2 week enter trial . Informed consent Little ability selfcare Used DMARD methotrexate receive intraarticular , intramuscular , intravenous corticosteroid 4 week screen . Topical vitamin A ( Neotigason CR ) D analog preparation ( Daivonex CR ) , anthralin psoriasis within 2 week baseline . Concurrent treatment MTX dosages &gt; 15 mg/week and/or corticosteroid prednisoneequivalent dosage &gt; 10 mg/day . Prior antiTNF therapy time . Infected joint prosthesis previous 5 year . Serious infection , hepatitis , pneumonia , pyelonephritis previous 3 month . Any chronic infectious disease renal infection , chest infection bronchiectasis sinusitis . Active tuberculosis require treatment within previous 3 year . Opportunistic infection herpes zoster within previous 2 month . Any evidence active cytomegalovirus ; active Pneumocystis carinii ; drugresistant atypical mycobacterial infection . Known hypersensitivity murine proteins Current sign symptom severe , progressive , uncontrolled renal , hepatic , haematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological , cerebral disease . A history lymphoproliferative disease include lymphoma sign suggestive disease , lymphadenopathy unusual size location ( ie , lymph node posterior triangle neck , infraclavicular epitrochlear , periaortic area ) ; splenomegaly . Any known malignant disease except basal cell carcinoma currently past 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>TNF-α</keyword>
	<keyword>Cardiovascular risk</keyword>
	<keyword>Immunomodulatory activity</keyword>
</DOC>